Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2010
  • Online publication date: December 2010

Chapeter 10 - Evaluation and management of neurogenic sexual dysfunction

from Section 2 - Evaluation and management

Summary

There are a number of neurological diseases which have an effect on bowel function. This chapter provides an overview of gastrointestinal (GI) physiology, with reference to the hindgut and pelvic floor. It addresses the problems caused by common neurological diseases. The intra-abdominal GI tract is varied, and divided into the organs of stomach, small intestine and large intestine. Bowel dysfunction affects approximately 80% of those with spinal cord injury (SCI) and causes more of a problem than urinary and sexual dysfunction in a third of individuals with SCI. Neurological diseases such as SCI or MS frequently impair CNS control of the gut. The difference between the neural control systems for bowel and bladder is underlined by the differing effects of such diseases on the two systems. Supraconal SCI tends to cause difficulty with evacuation of feces in addition to fecal incontinence, but predominantly difficulty with urinary continence.

References

1. Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1:35–9.
2. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med 2007;4:241–50.
3. Laumann EO, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–44.
4. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762–74.
5. Foley F, Werner M. Sexuality and intimacy. In: Kalb R, ed. Multiple sclerosis: the questions you ask, the answers you need. New York: Demos Vermonde Press; 2000.
6. Hulter BM, Lundberg PO. Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:83–6.
7. Nortvedt MW, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7:231–5.
8. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
9. Borello-France D, Leng W, O'Leary M, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler 2004;10:455–61.
10. Aisen M, Sanders A, eds. Sexual dysfunction in neurologic disease: mechanisms of disease and counselling approaches. AUA Update Series Lesson 35; 1998.
11. Annon JS. PLISSIT therapy. In: Corsini R, ed. Handbook of Innovative Psychotherapies. New York: Wiley & Sons; 1981:626–39.
12. Annon JS, Robinson CH. The use of various teaching models in treatment of sexual concerns. In: Piccolo JL, Piccolo LL, eds. Handbook of sexual therapy. New York: Plenum Press; 1978.
13. McBride KE, Rines B. Sexuality and spinal cord injury: a road map for nurses. SCI Nurs 2000;17:8–13.
14. Valleroy ML, Kraft GH. Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehabil 1984;65:125–8.
15. Kirkeby HJ, Poulsen EU, Petersen T, Dorup J. Erectile dysfunction in multiple sclerosis. Neurology 1988;38:1366–71.
16. Staerman F, Guiraud P, Coeurdacier P, et al. Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis. Int J Impot Res 1996;8:241–5.
17. Betts CD, Jones SJ, Fowler CG, Fowler CJ. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117(Pt 6):1303–10.
18. Vas CJ. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969;45:166–82.
19. Witt MA, Grantmyre JE. Ejaculatory failure. World J Urol 1993;11:89–95.
20. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30.
21. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
22. Kalichman SC, Rompa D. Sexual sensation seeking and sexual compulsivity scales: reliability, validity, and predicting HIV risk behavior. J Pers Assess 1995;65:586–601.
23. Fowler CJ. The neurology of male sexual dysfunction and its investigation by clinical neurophysiological methods. Br J Urol 1998;81:785–95.
24. Stief CG, Djamilian M, Anton P, et al. Single potential analysis of cavernous electrical activity in impotent patients: a possible diagnostic method for autonomic cavernous dysfunction and cavernous smooth muscle degeneration. J Urol 1991;146:771–6.
25. Jiang XG, Speel TG, Wagner G, Meuleman EJ, Wijkstra H. The value of corpus cavernosum electromyography in erectile dysfunction: current status and future prospect. Eur Urol 2003;43:211–8.
26. Ward-Abel N. Sexuality & MS: a guide for women. Letchworth Garden City, UK: Multiple Sclerosis Trust; 2007.
27. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
28. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275–87.
29. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67–85.
30. Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004;65:62–7.
31. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736–46.
32. Saiz-Ruiz J, Montes JM, Ibanez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol 2005;20:435–40.
33. Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med 2009;6:1248–58.
34. Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700–5.
35. Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999;46:15–21.
36. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998;52:375–9.
37. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421–6.
38. Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction. http://www.uroweb.org/fileadmin/tx_eauguidelines/Erectile%20Dysfunction.pdf. 2005:1–28.
39. Hackett G, Kell P, Ralph D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5:1841–65.
40. Gacci M, Del Popolo G, Macchiarella A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178:2040–3.
41. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am 2007;36:465–79.
42. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371–4.
43. Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol 2007;91:1551–5.
44. Pavone C, Curto F, Anello G, et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004;172(6 Pt 1):2347–9.
45. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271–5.
46. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001;28:335–41.
47. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol 1996;155:1609–12.
48. Hirsch IH, Smith RL, Chancellor MB, et al. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994;32:661–4.
49. Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine 2004;23:149–55.
50. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1–7.
51. Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160(6 Pt 1):2041–6.
52. Goldstein I, Newman L, Baum N, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997;157:833–9.
53. Carson CC. Penile prostheses: are they still relevant? BJU Int 2003;91:176–7.
54. Claes H, van Hove J, van de Voorde W, et al. Pelvi-perineal rehabilitation for dysfunctioning erections. A clinical and anatomo-physiologic study. Int J Impot Res 1993;5:13–26.
55. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994;48:133–6.
56. Sperling H, Lorenz A, Krege S, Arndt R, Michel MC. An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. J Urol 2002;168:160–3.
57. Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. Midodrine improves ejaculation in spinal cord injured men. J Urol 2007;178:2082–6.
58. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 2009;6:30–9.
59. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005–17.
60. Ziaei S, Moaya M, Faghihzadeh S. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. Climacteric 2010;13:249–53.
61. Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res 2005;17:399–408.
62. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55:812–5.
63. Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189–93.
64. Wilson SK, Delk JR, 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54–8.
65. Canavan TP, Heckman CD. Dyspareunia in women. Breaking the silence is the first step toward treatment. Postgrad Med 2000;108:149–52, 157–60, 164–6.
66. Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001;185:1332–7.
67. Tiefer L, Schuetz-Mueller D. Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995;22:767–73.
68. Stravynski A, Gaudette G, Lesage A, et al. The treatment of sexually dysfunctional men without partners: a controlled study of three behavioural group approaches. Br J Psychiatry 1997;170:338–44.
69. McCarthy BW. Relapse prevention strategies and techniques in sex therapy. J Sex Marital Ther 1993;19:142–6.